Pembrolizumab emerged as the most efficient immunotherapeutic strategy in the context of GC, particularly in the subset of patients with the dMMR/MSI-H phenotype tumors and tumors expressing PD-L1. The gene discussed is CD274; the disease is gastric cancer.